Shamburg News · 8-K filed Nov 13, 2026, 8:05 AM EST
PAVmed Reports Preliminary Q3 2026 Results and Business Update
PAVM · PAVmed Inc.
- Earnings
- Reg FD disclosure
- Materiality: high
PAVmed Inc. issued a press release on November 13, 2026 reporting preliminary financial results for the quarter ended September 30, 2026 and a business update. The company reported approximately $6.8 million in operating expenses, including $1.0 million of stock-based compensation, and a non-GAAP adjusted net loss of approximately $1.2 million, or $(0.19) per share. Lucid Diagnostics began receiving Medicare payments for EsoGuard in October, and cash and cash equivalents were $8.9 million, including $5.3 million of restricted cash, as of September 30, 2026.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001493152-26-051544.
Written from the filing by Shamburg Markets. Figures are as reported by the company.